Compare Novo Nordisk A/S (NVO) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rocket Lab USA Inc — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while Rocket Lab USA Inc trades at $68.24 (market cap $43.74B). The key difference: Novo Nordisk A/S is far larger — about 3.8× Rocket Lab USA Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rocket Lab USA Inc for 29 Days on average.
| NVO | RKLB | |
|---|---|---|
Market Cap | $165.31B | $43.74B |
Volume | 11,432,838 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $63.98 | $150.23 |
52-Week Low | $35.29 | $39.48 |
Typical Hold Time | 116 Days | 29 Days |
Enterprise Value | $179.56B | $41.57B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Rocket Lab (RKLB) trades at $68.21, down 5.16% today, amid a bearish technical signal despite recent positive business developments. The company secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. However, financials show negative profitability with a net income margin of -21.51% and elevated valuation ratios including P/S of 51.96. Technical indicators show bearish momentum with key support at $64.
The outlook remains mixed with strong analyst bullishness (76% buy ratings, $107 consensus target) contrasting with fundamental challenges. Investment opportunity lies in execution of the growing launch backlog and Neutron rocket development, while risks include sustained losses, SpaceX competition, and high valuation multiples requiring significant future growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
